Editas Medicine (EDIT) Common Equity (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Common Equity data on file, last reported at $27.3 million in Q4 2025.

• Common Equity for Q4 2025 came in at $27.3 million, down 79.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $27.3 million (down 79.68% YoY), and the FY2025 annual result was $27.3 million, down 79.68% from the prior year.
• Common Equity advanced to $27.3 million in Q4 2025 per EDIT's latest filing, from $13.5 million in the prior quarter.
• Over five years, Common Equity peaked at $638.0 million in Q1 2021 and troughed at $13.5 million in Q3 2025.
• A 5-year average of $326.6 million and a median of $354.8 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2021 and 2025: Common Equity jumped 171.99% in 2021, then plunged 92.34% in 2025.
• A 5-year view of Common Equity shows it stood at $553.6 million in 2021, then slumped by 34.85% to $360.7 million in 2022, then declined by 3.21% to $349.1 million in 2023, then plunged by 61.54% to $134.3 million in 2024, then tumbled by 79.68% to $27.3 million in 2025.
• Business Quant data shows EDIT's Common Equity at $27.3 million in Q4 2025, $13.5 million in Q3 2025, and $19.2 million in Q2 2025.